On May 6, 2024, Anila Lingamneni, Executive Vice President and Chief Technology Officer of Haemonetics Corporation (NYSE:HAE) sold 2,305 shares of the company's stock. The transaction is documented in his recent SEC filings. The sale was part of a series of transactions over the past year, in which insiders sold a total of 6,914 shares.
Haemonetics Corp (NYSE:HAE) specializes in products for blood and plasma collection and processing. The company offers a variety of integrated solutions that improve the safety, efficiency and effectiveness of blood supply chains in healthcare.
On the date of the sale, Haemonetics' stock was priced at $95, giving it a market capitalization of approximately $4.74 billion. The company has a price-to-earnings ratio of 37.91, which is higher than the industry median of 30.22.
According to GF Value, Haemonetics Corp's estimated intrinsic value is $93.53 per share, and the price to GF value ratio is 1.02, giving the stock a fair value.
Haemonetics Corp's insider trading history shows that there were no insider buys in the past year, and a total of 7 insider sells in the same period.
GF Value is calculated based on historical multiples such as price-to-earnings ratio, price-to-sales ratio, price-to-book ratio, price-to-free cash flow, adjusted by GuruFocus factors that reflect past earnings and growth, and subject to the following conditions: is supplemented with Future performance forecasts by Morningstar analysts.
This article created by GuruFocus is intended to provide general insight and is not intended as financial advice. Our commentary is based on historical data and analyst forecasts using an unbiased methodology and is not intended to serve as specific investment guidance. It does not constitute a recommendation to buy or sell stocks, and does not take into account your individual investment objectives or financial situation. Our objective is to provide fundamental data-driven analysis over time. Please note that our analysis may not incorporate the latest announcements or qualitative information from price-sensitive companies. GuruFocus has no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
